Small Caps
Page 2 of 2 · 33 articles on this desk
Small Caps coverage, page 2
Evolution Petroleum Prices $12 Million Stock Sale at $3.25 to Help Fund $16 Million Midland Basin Royalty Purchase
The NYSE American-listed producer priced 3.7 million shares at $3.25 on Aug. 19, with closing expected Aug. 20, to part-fund roughly 3,420 net royalty acres in the Permian. Shares closed at $3.34, down 12.79% on the day.
XTEND's European NATO Contract Is Valued at Up to $15 Million, With About $4.5 Million Secured for the First Year
JFB Construction Holdings said Monday that XTEND, the drone maker it is merging with, signed a multi-year contract with an unnamed European NATO member's defense ministry. The release puts the ceiling at up to approximately $15 million and describes approximately $4.5 million as secured for the first year, with the balance dependent on additional orders and the customer exercising options under the framework agreement. It also moves the expected closing of the merger itself to Sept. 8, a week later than the date given six days earlier.
NRx Says Its Ketamine Generic Cleared First-Cycle FDA Review With One Item Left — and Already Submitted. That Application Is the Anesthesia Label, Not Depression.
NRx Pharmaceuticals told investors Monday afternoon that the FDA has finished first-cycle review of its generic ketamine filing, and that the one remaining item, a manufacturer's attestation on the vial, has already been sent to the agency. Monday's release never says what that filing covers; an earlier NRx release does — the drug's existing anesthesia label. The depression indication runs through a separate NRX-100 application the company said Monday it is still finalizing.
Anavex Stockholders Vote on the Whole Board Sept. 24. The Cure Period for Its Late 10-Q Could Run to Nov. 16 — If Nasdaq Accepts the Plan.
PVG Asset Management, which says it holds 327,344 Anavex shares, is running six nominees against a slate the company refreshed after a committee of independent directors terminated its chief executive in April for what it classified as Cause under his employment agreement. The company's own 8-K describes an exchange exception that could run to Nov. 16 — almost eight weeks after the meeting — but only if Nasdaq accepts its compliance plan.
Savara's FDA Decision Date Is Not This Saturday. It Moved to Nov. 22 Four Months Ago.
Savara said on April 15 that the FDA had pushed its MOLBREEVI review back three months after deeming the company's answers to agency questions a major amendment. Of three published PDUFA calendars we read on Monday morning, one still carried only the superseded August 22 date and a second carried it alongside the corrected one.
Quantum Corporation Booked a $155.3 Million Loss on 22 Million Shares. It Had 39.4 Million by August.
The data-storage company's fiscal first-quarter 10-Q shows a $5.0 million operating profit sitting above a $155.3 million net loss. Three fair-value and extinguishment charges tied to June's debt-for-equity recapitalization account for $157.7 million, and the cash flow statement treats all but about $3.3 million of them as non-cash. The per-share figure is struck on a weighted-average count barely half the shares outstanding on August 6, and the September quarter is the first that will carry the new count for its full length.
Exzeo Spent a $12 Million Buyback in Six Weeks. Friday Afternoon It Authorized $25 Million More.
The insurance-technology company announced the larger program after Friday's close. Its own filings show the first one repurchased 834,250 shares in about six weeks — roughly a tenth of the stock it sold in its IPO — while majority holder HCI Group's reported stake stood at about 83.1 percent at June 30.
Elutia Assembles Up to $26 Million Without Selling Stock, Betting the Company on One Device
The $42 million medtech said after Thursday's close that it had lined up a $15 million Avenue Capital loan facility and up to $11 million from selling its SimpliDerm business, enough in management's view to carry NXT-41x through FDA clearance and full commercial launch. Chief executive Randy Mills stressed the company did it without an equity offering. The catch is that most of the money is contingent, and one tranche is unlocked only by the very clearance it is meant to fund.
Small Caps Take the Record Alone: Russell 2000 Closes at 3,068.42 as the Big Three Fade Into the Weekend
The small-cap benchmark finished Friday at a record 3,068.42 and gained 1.11% on the week, outrunning the S&P 500, Dow and Nasdaq on a session when energy and basic materials led and Treasury yields backed up.
July Retail Sales Fell 0.6%. The Russell 2000 Owns More of That Miss Than the S&P Does
The Census Bureau's advance July estimate landed at $763.6 billion, down 0.6% from June against calendar forecasts that sat above zero. For an index that earns roughly four-fifths of its revenue inside the United States, the category detail matters more than the headline.
Blaize cuts its 2026 revenue outlook by two-thirds while CPI Aerostructures posts a profit: Thursday night's small-cap earnings
Three small companies reported after Thursday's close and told three different stories. Blaize took its full-year revenue guidance from $130 million to $40-$43 million, CPI Aerostructures turned a 4.4% gross margin into 22%, and CapsoVision grew revenue 10% while its operating loss widened by more than half.
Fossil Raises Its Outlook While Jack in the Box Pays Up for Debt: Two Small-Cap Consumer Reports Land After Wednesday's Close
Fossil Group lifted full-year guidance on a 490-basis-point gross margin gain even as sales fell, sending shares higher in extended trading. Jack in the Box posted another quarter of negative same-store sales and disclosed the price of the refinancing that fixed its maturity wall.
Small caps finish ahead of the large-cap benchmarks as July CPI lands in line
The Russell 2000 closed Wednesday up 0.61% at 3,045.56, outpacing the S&P 500's 0.26% gain and a Dow that finished slightly lower. The official prints show small caps took the in-line inflation report better than the mega-cap indexes did.
Small caps hold their gains as July CPI lands in line and traders lean toward a Fed hold
A soft headline inflation print and a 1.5% drop in energy prices kept the Russell 2000 in positive territory Wednesday, easing pressure on the rate-sensitive corner of the market.
Russell 2000 Edges Higher Ahead of CPI as Small-Business Optimism Hits One-Year High
Small caps outpaced the major averages in Tuesday morning trading, helped by the strongest NFIB optimism reading since last August, as investors braced for Wednesday's inflation report.